<DOC>
	<DOCNO>NCT01251614</DOCNO>
	<brief_summary>This study compare well adalimumab work versus methotrexate ( MTX ) child moderate severe psoriasis short term . It also study safe well adalimumab work long term long disease response maintain stop therapy .</brief_summary>
	<brief_title>A Double Blind Study Pediatric Subjects With Chronic Plaque Psoriasis , Studying Adalimumab vs. Methotrexate</brief_title>
	<detailed_description>The study 30-day screening period multi-period study design , describe : Period A - Primary Treatment Phase : Participants randomize receive adalimumab 0.8 mg/kg , adalimumab 0.4 mg/kg , MTX 1:1:1 ratio 16 week . Period B - Treatment Withdrawal Phase : Responders withdraw active treatment monitor loss disease control 36 week . Period C - Re-Treatment Phase : Participants experience loss disease control Period B re-treated adalimumab 16 week . Period D - Long-Term Follow-Up Phase : Participants receive adalimumab observe off-treatment ( disease remain control ) 52 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Subject ≥ 4 year &lt; 18 year age ; 2 . Subject weigh ≥ 13 kg ; 3 . Subject must fail respond topical therapy ; 4 . Subject must need systemic treatment control his/her disease meet one follow : Physician 's Global Assessment ( PGA ) ≥ 4 Body surface area ( BSA ) involve &gt; 20 % Very thick lesion BSA &gt; 10 % Psoriasis Area Severity Index ( PASI ) &gt; 20 PASI &gt; 10 least one following : Active psoriatic arthritis unresponsive nonsteroid antiinflammatory drug ( NSAIDs ) Clinically relevant facial involvement Clinically relevant genital involvement Clinically relevant hand and/or foot involvement Children 's Dermatology Life Quality Index ( CDLQI ) &gt; 10 5 . If subject &lt; 12 year age reside geographic region heliotherapy practical , subject must fail respond , intolerant , contraindication heliotherapy , suitable candidate heliotherapy ; 6 . If ≥ 12 year age , subject must fail respond , intolerant , contraindication phototherapy , suitable candidate phototherapy ; 7 . Subject must clinical diagnosis psoriasis least 6 month determine subject 's medical history confirmation diagnosis physical examination Investigator ; 8 . Subject must stable plaque psoriasis least 2 month prior Baseline 1 . Prior biologic use prior treatment etanercept ; 2 . Treatment etanercept therapy within 4 week prior Baseline visit ; 3 . Methotrexate ( MTX ) use within past year prior MTX use time subject respond , tolerate MTX ; 4 . Contraindication treatment MTX study ; 5 . Erythrodermic psoriasis , generalize localized pustular psoriasis , medicationinduced medication exacerbate psoriasis new onset guttate psoriasis ; 6 . Infection ( ) require treatment intravenous ( IV ) antiinfectives within 30 day prior Baseline Visit oral antiinfectives within 14 day prior Baseline Visit ; 7 . Treatment psoriasis topical therapy corticosteroid , vitamin D analog , retinoids within 7 day prior Baseline visit ; 8 . Treatment psoriasis ultraviolet ( UV ) B phototherapy , excessive sun exposure , use tan bed within 7 day prior Baseline visit ; 9 . Treatment psoriasis ultraviolet A psoralen ( PUVA ) phototherapy , nonbiologic systemic therapy treatment psoriasis , systemic therapy know improve psoriasis within 14 day prior Baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Chronic plaque psoriasis</keyword>
	<keyword>Pediatric</keyword>
</DOC>